Incyte Stock News

NEW YORK and VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that Mary Crowley Cancer Research center in Dallas, Texas is now actively screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCells lead candidate, Bria-IMT, with Incytes checkpoint inhibitors, retifanlimab and epacadostat.

Walleye Capital LLC cut its holdings in Incyte Co. (NASDAQ:INCY) by 14.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,230 shares of the biopharmaceutical companys stock after selling 530 shares during the period. Walleye Capital LLCs holdings in Incyte were worth $272,000 as of its []

The rejection of its PD-1 inhibitor, retifanlimab, was never going to be the end of Incytes checkpoint story. Not only was the biotech holding out hope of changing the FDAs mind and testing the cancer drug in multiple combinations, it also lined up a trio of oral PD-L1 candidates as

Incyte's Increase In Jakafi's Sales Guidance Implies 29% Upside In The Valuation

Incyte Corporation (INCY) CEO Herve Hoppenot on Q3 2021 results - Earnings Call Transcript

Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mant

Incyte Corporation (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.

It's much too early to count these companies out.

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

A screening of healthcare stocks in the S&P 500 reveals that investors may find plenty of upside in three members of the index, according to an article in Barron's. The analysis showed that Vertex Pha

Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADVCongress--Incyte Announces Full Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients with Vitiligo